226 results on '"Mayer-Hamblett, N."'
Search Results
2. Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis
3. Building global development strategies for cf therapeutics during a transitional cftr modulator era
4. WS03.05 Multicenter validation of the cystic fibrosis-ABLE score as a predictor of outcome and therapeutic response in cystic fibrosis
5. P090 Treatment use among SIMPLIFY trial participants through 24 weeks of follow-up
6. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa
7. Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials
8. Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study
9. Heterogeneity and Disparities in the Use of Exception Scores in Pediatric Liver Allocation
10. 35 Approaches that use historical controls to meet modern needs in cystic fibrosis clinical trials
11. 261 Concentrations of elexacaftor/tezacaftor/ivacaftor in the cystic fibrosis population: Interim analysis of the CHEC-Pharmacokinetics study
12. 43 Cystic fibrosis transmembrane conductance regulator modulator–induced sweat chloride changes in the cystic fibrosis population from the Characterizing Cystic Fibrosis Transmembrane Conductance Regulator–Modulated Changes in Sweat Chloride Study: 2022 Update
13. Rate of lung function decline in patients with cystic fibrosis (cf) having a residual function gene mutation: P255
14. 47: A new path for CF clinical trials through the use of historical controls
15. 555: Clinical trial interest after establishment of modulator therapy: Interim CHEC-SC survey results
16. P084 Willingness of people treated with elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized clinical trials of new modulators and inhaled antibiotics
17. WS05.05 Randomised withdrawal of hypertonic saline in those with lower lung function after receiving elexacaftor/tezacaftor/ivacaftor; a sub-study of the SIMPLIFY Trial
18. SOCIOECONOMIC STATUS AND ACCESS TO LUNG TRANSPLANTATION FOR ADULT CYSTIC FIBROSIS PATIENTS IN THE UNITED STATES: 415★
19. PSEUDOMONAS AERUGINOSA (PA) PHENOTYPES ASSOCIATED WITH PERSISTENT EARLY INFECTION IN CF PATIENTS IN THE EPIC CLINICAL TRIAL: 266*
20. RISK FACTORS FOR CHRONIC KIDNEY DISEASE IN ADULTS WITH CYSTIC FIBROSIS: 527
21. Markers of Increased Disease Severity Are Present Among Adults with Cystic Fibrosis with FEV1Less Than 40% Predicted Prior to Lung Transplant Referral
22. Important steps in the journey to highly effective CFTR modulator access for people with CF
23. REFINEMENTS IN NASAL POTENTIAL DIFFERENCE MEASUREMENT FOR MULTI-CENTER CLINICAL TRIALS: 269
24. Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis
25. WS01-3 IV gallium nitrate demonstrates biological activity for chronic Pseudomonas aeruginosa infection in cystic fibrosis
26. The cystic fibrosis therapeutics development network (CF TDN): a paradigm of a clinical trials network for genetic and orphan diseases
27. In statistics we trust: Towards the careful derivation and interpretation of meaningful survival estimates in cystic fibrosis
28. Another step in the journey: From CFTR mutation to sweat chloride concentration to survival
29. P255 Rate of lung function decline in patients with cystic fibrosis (cf) having a residual function gene mutation
30. 65 Physician assessment of blinded adverse events in RCTs in cystic fibrosis
31. 54 Relationship between rate of percent predicted FEV1 (ppFEV1) decline and baseline and acute change in ppFEV1 in patients (pts) with cystic fibrosis (CF) treated with lumacaftor/ivacaftor (LUM/IVA)
32. Corrigendum to “Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study” [J Cyst Fibros (2015) 632–638]
33. WS02.1 Efficacy of a protocol for eradication of newly acquired MRSA: Results of the STAR-too trial
34. 112 Analysis of long-term use of liposomal amikacin for inhalation (LAI) in patients with cystic fibrosis (CF) who have chronic infection from Pseudomonas aeruginosa
35. WS7.3 Once-daily liposomal amikacin for inhalation is noninferior to twice-daily tobramycin inhalation solution in improving pulmonary function in cystic fibrosis patients with chronic infection due to Pseudomonas aeruginosa
36. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: The early intervention in cystic fibrosis exacerbation (eICE) trial
37. In Vitro Antibiotic Susceptibility of Initial Pseudomonas aeruginosa Isolates From United States Cystic Fibrosis Patients
38. Few Patient, Treatment, and Diagnostic or Microbiological Factors, Except Complications and Intermittent Negative Cerebrospinal Fluid (CSF) Cultures During First CSF Shunt Infection, Are Associated With Reinfection
39. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis
40. A Phase I/II Study of the Anti-PcrV Antibody KB001 in Cystic Fibrosis Patients with Pseudomonas aeruginosa.
41. Advancing Outcome Measures for the New Era of Drug Development in Cystic Fibrosis
42. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
43. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis.
44. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis.
45. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.
46. P255 Rate of lung function decline in patients with cystic fibrosis (cf) having a residual function gene mutation
47. Response.
48. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.
49. Characteristics of individuals with cystic fibrosis in the United States ineligible for ivacaftor and elexacaftor/tezacaftor/ivacaftor.
50. Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa After Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.